0, 1 week 127.0±8.2 (p=0.024), 12 weeks 159.1±9.3 (p<0.001), 16 weeks 181.8±8.6 (p<0.001), post 12 weeks 107.6± 10.5 (p=0.573), APRIL; before 100.0; 1 week 248.3±27.7 (p<0.001); 12 weeks 198.8±29.9 (p=0.019); 16 weeks 249.6±27.7 (p<0.001); post 12 weeks 110.0±29.9 (p=0.810)]. Serum levels of C3 and C4 immediately increased at 1 week, but gradually decreased during the compound screening assay therapy. Serum level of IgG independently decreased through the observed period. The mRNA expression of CD69 and CD71 significantly increased at 1 and 1 6 weeks, then decreased after the end of therapy, indicating that the B cells were activated in these periods. Conclusion: The B cell

activating factors, BAFF and APRIL, were secreted through the TVR therapy. These cytokines may induce abnormal activation of B cells, and exhaustion of complements through the TVR therapy in patients with CH-C. Disclosures: Michio Imawari – Advisory Committees or Review Panels: Shionogi Pharmaceutical Co.; Consulting: Ajinomoto; Speaking and Teaching: Tanabe Mitsubishi Pharmaceutical Co., Yansen Pharma, Dainippon Sumitomo Pharmaceutical Co., Taisho Toyama Pharmaceutical Co., Tohre, Meiji Seika Pharma, GSK, MSD, Dai-ichi Sankyo, Chugai Pharmaceutical Co., Takeda Pharmaceutical Co., Ehzai The following people have

nothing to disclose: Manabu Uchikoshi, Takayoshi Ito, Jun Arai, Yuu Shimozuma, Miyuki Miyashita, Kenichi Morikawa, Junichi Eguchi, Hisako Nozawa, Tomoe IWR-1 supplier Shimazaki, Hitoshi Yoshida Background and Aims. Metabolic alterations occurring in HCV infection, especially insulin resistance (IR), have been associated with accelerated progression of liver fibrosis, increased incidence of hepatocellular

carcinoma (HCC) and reduced viro-logical response to antiviral therapy. The patatin-like phospho-lipase-3 (PNPLA3) variant I148M (rs738409), 上海皓元 involved in hepatic fat accumulation and hepatic fibrogenesis in NAFLD, has been recently associated with IR and increased hepatic steatosis also in HCV genotype 2 (HCV-G2) infected patients. Since the impact of PNPLA3 in HCV-G1 infection has never been explored, we evaluated the correlation between the PNPLA3 genotype and IR in a well characterized HCV-G1 cohort. Methods. One hundred and seventy-nine G1-CHC patients consecutively biopsied in two centers were genotyped for PNPLA3 rs738409 SNP. Insulin resistance has been evaluated by homeostasis model assessment (HOMA-R). All biopsies were scored for staging and grading and steatosis >30% was defined as moderate/severe. Results. The PNPLA3 GG homozy-gosis was detected in 7% of HCV-G1 infected patients. Subjects carrying the GG genotype had higher BMI (p=0.05) and higher insulin levels (p=0.006). Insulin resistance was significantly higher in patients carrying the GG genotype vs patients with CC/CG (HOMA-IR = 3.83 ± 2.2 vs 2.76 ± 1.7; p=0.039).